Uncategorized

Edgewise Therapeutics Q1 EPS $(0.14)

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.14) per share.

byBenzinga Newsdesk

May 13, 2021

1 minute read

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.14) per share.

Hopeful Golden Cross Forms On ResMed’s Chart

By Benzinga Insights

September 22, 11:14 AM

If history is any guide, there may be good fortune ahead for shares of ResMed (NYSE:RMD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

RMD

Douglas Dynamics Sees FY22 Sales $600M-$630M Vs $608M Est., Adj. EPS $1.65-$2.05 Vs $1.81 Est., Adj. EBITDA $80M-$95M

By Michael Horton

October 31, 5:32 PM

Outlook McCormick stated, "We are raising and narrowing our guidance ranges today given our robust performance so far this year, plus the positive demand trends we see and strong backlog in our Solutions

PLOW

Seelos Therapeutics Shares Spike Higher; Co Confirms Earlier Report To Acquire Exclusive License Of iX Biopharma’s Proprietary Wafer-Based Delivery Platform For Sublingual Ketamine For Upfront Fee Of $9M

By Benzinga Newsdesk

November 24, 9:19 AM

Seelos plans to evaluate sublingual ketamine, now named SLS-003, in pain indications such as chronic neuropathic pain and Complex Regional Pain Syndrome (CRPS) and in additional psychiatric disorders, including

SEEL

Why Apple Shares Are Falling

By Henry Khederian

May 5, 11:56 AM

Shares of several companies in the broader tech sector, including Apple Inc (NASDAQ: AAPL), are trading lower amid overall weakness as traders continue to digest Wednesday's Fed rate hike announcement. An increase in yields has pressured tech and growth stocks.

AAPL

Edgewise Therapeutics Q1 EPS $(0.14)

Related Posts

Hopeful Golden Cross Forms On ResMed’s Chart

Douglas Dynamics Sees FY22 Sales $600M-$630M Vs $608M Est., Adj. EPS $1.65-$2.05 Vs $1.81 Est., Adj. EBITDA $80M-$95M

Seelos Therapeutics Shares Spike Higher; Co Confirms Earlier Report To Acquire Exclusive License Of iX Biopharma’s Proprietary Wafer-Based Delivery Platform For Sublingual Ketamine For Upfront Fee Of $9M

Why Apple Shares Are Falling